Yahoo
NasdaqCM - Delayed Quote USD

Polyrizon Ltd. (PLRZ)

11.24 -1.18 (-9.46%)
At close: September 4 at 4:00:00 PM EDT
11.47 +0.23 (+2.05%)
After hours: September 4 at 7:30:03 PM EDT
Chart Range Bar
Loading chart for PLRZ
  • Previous Close 12.41
  • Open 12.40
  • Bid 8.87 x 200
  • Ask 15.47 x 200
  • Day's Range 11.07 - 12.72
  • 52 Week Range 2.88 - 18.20
  • Volume 141,280
  • Avg. Volume 62,561
  • Market Cap (intraday) 26.662M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -4.90
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.

www.polyrizon-biotech.com

2

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PLRZ
32.39%
S&P 500 (^GSPC)
12.75%

1-Year Return

PLRZ
75.08%
S&P 500 (^GSPC)
18.71%

3-Year Return

PLRZ
99.54%
S&P 500 (^GSPC)
70.93%

5-Year Return

PLRZ
99.54%
S&P 500 (^GSPC)
70.18%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -28.95%

  • Return on Equity (ttm)

    -25.38%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -3.33M

  • Diluted EPS (ttm)

    -4.90

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    12.27M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -2.57M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: